Scope
The short answer
Synthesis by-products such as deletion sequences behave much like the target peptide on a column, so an HPLC purity number can look clean while close relatives sit under the main peak. Pairing HPLC (how much) with LC-MS (of what) is how reports address that.
This guide explains laboratory analysis of research materials. It makes no claims about human or veterinary use, and these products are sold for research use only.
Why a purity number is not the whole story
A certificate of analysis (COA) for a research peptide usually shows a purity figure from HPLC, such as 99.84%. That number is easy to read and easy to over-read. Purity by HPLC is the main peak’s share of the total detected signal. It says how much of the signal belongs to the main peak, not what the peak is.
Where impurities come from
Most research peptides are made by solid-phase peptide synthesis, where amino acids are added one at a time. A review of impurities in peptide medicines groups them into three families: by-products of synthesis (such as deletions, insertions, racemization and side-chain adducts), degradation products (such as diketopiperazine and succinimide formation), and products of interaction with other ingredients in a formulation [1].
A deletion sequence is a chain missing one amino acid because a coupling step did not finish. A truncated peptide stops early. The American Peptide Society notes that deletions and truncations remain significant contaminants even at high coupling efficiency, and as an illustration states that a 30-amino-acid peptide can carry more than 25% truncations at 99% coupling efficiency before purification [2]. That is why purification matters, and why the finished lot is tested.
Why HPLC can miss close relatives
RP-HPLC separates molecules by how strongly they stick to a column. A chain missing one amino acid behaves very much like the full chain, so the two can elute at nearly the same time. The same American Peptide Society page makes this point: impurities with similar properties can co-elute and be overlooked by standard HPLC [2]. Method choices such as the gradient and the detection wavelength change how well close species separate.
This is a limit of the method, not a flaw in any one report. HPLC answers “how much of the signal is the main peak.” It does not answer “is the main peak the right molecule.” Compound Brief makes the same distinction: HPLC answers how much, LC-MS answers of what [3].
What LC-MS adds
LC-MS measures mass-to-charge ratio. A deletion sequence has a different mass from the target, so mass spectrometry can flag it even when HPLC shows a single clean peak. The HPLC vs. LC-MS guide covers the two methods in more depth.
How to read this on a real report
- Find the purity method and wavelength (for example RP-HPLC at 214 nm).
- Find a separate identity method (for example LC-MS/MS) and its result.
- Match the lot number on the report to the lot on the label.
- Confirm the COA number with the testing laboratory itself.
As a worked example, Glutathione 1500 mg, COA9236 (lot GTTZ5B-Z04, report dated September 13, 2026) lists 99.84% purity by RP-HPLC at 214 nm, 1507.04 mg measured against a 1500 mg label, and identity by LC-MS/MS reported as conforming [4]. For how purity and content differ, see purity vs. peptide content. The COA library shows more reports.
Limitations and risks of over-reading a COA
A COA applies only to the sample tested, and one report cannot show that every vial in a lot is identical. Percent-area purity does not detect everything: impurities that co-elute, or that respond differently to the detector, can be under- or over-counted. Identity by mass spectrometry confirms a mass, not the full structure or stereochemistry, so racemization can pass unnoticed. A COA also does not by itself establish sterility, endotoxin levels or long-term stability. Always read the method line, the date and the laboratory’s own verification step.
References
- D’Hondt M, et al. “Related impurities in peptide medicines.” J Pharm Biomed Anal. 2014;101. (Abstract read via Europe PMC.)
- American Peptide Society, “Peptide Purification.”
- Compound Brief, “HPLC vs LC-MS.” (Published by DAAVY.)
- DAAVY Research, COA9236 (Bioviridian), report dated September 13, 2026.
References 1 and 2 are a review abstract and a society educational page; the 25% figure is that page’s own illustration, not a measurement of any DAAVY lot.
